MCID: BLD032
MIFTS: 41

Bile Duct Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Bile Duct Adenocarcinoma

MalaCards integrated aliases for Bile Duct Adenocarcinoma:

Name: Bile Duct Adenocarcinoma 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4896
NCIt 50 C27813
SNOMED-CT 68 70179006
UMLS 73 C1370800

Summaries for Bile Duct Adenocarcinoma

Disease Ontology : 12 A bile duct carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bile Duct Adenocarcinoma is related to adenocarcinoma and extrahepatic bile duct adenocarcinoma. An important gene associated with Bile Duct Adenocarcinoma is PRRT2 (Proline Rich Transmembrane Protein 2), and among its related pathways/superpathways are Gastric cancer and Development EGFR signaling pathway. The drugs Trioxsalen and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and breast, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Bile Duct Adenocarcinoma

Diseases related to Bile Duct Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 222)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.8 CDH1 EPCAM HRAS KRAS MUC1 TP53
2 extrahepatic bile duct adenocarcinoma 12.5
3 papillary extrahepatic bile duct adenocarcinoma 12.3
4 ovarian germ cell cancer 10.4 AFP KRT7
5 intratubular embryonal carcinoma 10.4 AFP KRT7
6 vulvar intraepithelial neoplasia 10.3 KRT7 TP53
7 episodic kinesigenic dyskinesia 2 10.3 HRAS PRRT2
8 eyelid carcinoma 10.3 KRT7 MUC2
9 malignant ectomesenchymoma 10.3 HRAS S100A1
10 cerebellar astrocytoma 10.3 IDH1 TP53
11 endosalpingiosis 10.3 KRT7 MUC1
12 parachordoma 10.3 KRT7 MUC1
13 papillary tumor of the pineal region 10.3 MUC1 S100A1
14 secretory meningioma 10.3 KRT7 MUC1
15 middle ear adenoma 10.3 KRT7 MUC1
16 rare adenocarcinoma of the breast 10.3 KRAS TP53
17 hyperplastic polyposis syndrome 10.3 KRAS TP53
18 schimmelpenning-feuerstein-mims syndrome 10.3 HRAS KRAS
19 periampullary adenoma 10.3 HRAS KRAS
20 paronychia 10.3 HRAS KRAS
21 large intestine adenocarcinoma 10.3 CDH1 KRT7
22 linitis plastica 10.3 CDH1 KRT7
23 adenoid squamous cell carcinoma 10.3 CDH1 KRT7
24 syringocystadenoma papilliferum 10.3 KRAS MUC1
25 spitz nevus 10.3 HRAS TP53
26 tumor of exocrine pancreas 10.3 MUC1 MUC2
27 pancreatic intraductal papillary-mucinous neoplasm 10.3 MUC1 MUC2
28 cerebral convexity meningioma 10.3 CDH1 TP53
29 proliferating trichilemmal cyst 10.3 KRT19 KRT7
30 hepatoblastoma 10.3 AFP KRT7 TP53
31 endometrial adenocarcinoma 10.3 KRAS KRT7 TP53
32 mucinous adenofibroma 10.3 CEACAM5 KRT7
33 hematocele of tunica vaginalis testis 10.3 AFP CEACAM5
34 melanotic medulloblastoma 10.3 AFP CEACAM5
35 renal cell carcinoma, papillary, 1 10.3 HRAS KRT7 TP53
36 malignant peripheral nerve sheath tumor 10.3 MUC1 S100A1 TP53
37 testicular germ cell tumor 10.3 AFP HRAS TP53
38 thymus cancer 10.3 KRT7 MUC1 TP53
39 fibroepithelial basal cell carcinoma 10.3 CEACAM5 TP53
40 atypical follicular adenoma 10.2 CEACAM5 TP53
41 leukemia, chronic lymphocytic 2 10.2 HRAS KRAS TP53
42 differentiated thyroid carcinoma 10.2 HRAS KRAS TP53
43 cystadenoma 10.2 KRT7 MUC1 MUC2
44 teratoma 10.2 AFP KRT7 TP53
45 lymphohistiocytoid mesothelioma 10.2 CEACAM5 EPCAM
46 duodenum adenocarcinoma 10.2 KRAS KRT7 MUC2
47 esophageal adenosquamous carcinoma 10.2 CDH1 CEACAM5
48 mature teratoma 10.2 AFP KRAS TP53
49 cap polyposis 10.2 MUC2 MUC5AC
50 uterine carcinosarcoma 10.2 CDH1 HRAS TP53

Graphical network of the top 20 diseases related to Bile Duct Adenocarcinoma:



Diseases related to Bile Duct Adenocarcinoma

Symptoms & Phenotypes for Bile Duct Adenocarcinoma

GenomeRNAi Phenotypes related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.72 ANXA8L1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.72 S100A4
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.72 ANXA8L1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.72 ANXA8L1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.72 ANXA8L1 S100A4
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.72 ANXA8L1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.72 ANXA8L1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.72 S100A4
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.72 ANXA8L1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.72 ANXA8L1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.72 S100A4
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.72 S100A4
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 9.72 ANXA8L1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.72 HRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.72 ANXA8L1 HRAS KRT7 S100A4
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.72 KRT7
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.72 KRT7
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.72 ANXA8L1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.72 HRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.72 KRT7
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.72 HRAS

MGI Mouse Phenotypes related to Bile Duct Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.76 CDH1 EPCAM HRAS KRAS KRT19 MUC2
2 homeostasis/metabolism MP:0005376 9.73 AFP CDH1 EPCAM HRAS IDH1 KRAS
3 neoplasm MP:0002006 9.23 AFP CDH1 HRAS KRAS KRT19 MUC2

Drugs & Therapeutics for Bile Duct Adenocarcinoma

Drugs for Bile Duct Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trioxsalen Approved Phase 3 3902-71-4 5585
2
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
3
Gemcitabine Approved Phase 3 95058-81-4 60750
4 Dermatologic Agents Phase 3
5
s 1 (combination) Phase 3,Not Applicable
6 Photosensitizing Agents Phase 3
7 Hematoporphyrin Derivative Phase 3
8 Dihematoporphyrin Ether Phase 3
9 Ether Phase 3
10 Antimetabolites, Antineoplastic Phase 3,Phase 1
11 Immunologic Factors Phase 3,Phase 1
12 Antimetabolites Phase 3,Phase 1
13 Antiviral Agents Phase 3
14 Immunosuppressive Agents Phase 3
15 Anti-Infective Agents Phase 3
16 Hematoporphyrins Phase 3
17
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
18
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
19
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
21 Vitamin B Complex Phase 2
22 Vitamin B9 Phase 2
23 Trace Elements Phase 2
24 Nicotinic Acids Phase 2
25 Vitamins Phase 2
26 Micronutrients Phase 2
27 Vitamin B3 Phase 2
28
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
29 Folate Phase 2
30 Protein Kinase Inhibitors Phase 2
31
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
32 Liver Extracts Phase 1
33 Antibodies Phase 1
34 Antibodies, Monoclonal Phase 1
35 Immunoglobulins Phase 1
36
Bilirubin Not Applicable 635-65-4 5280352

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 S-1 and Photodynamic Therapy in Cholangiocarcinoma Completed NCT00869635 Phase 3 S-1 Chemotherapy
2 Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
3 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
4 Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting NCT03257761 Phase 1 Guadecitabine
5 Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery Withdrawn NCT03117855 Phase 1 Capecitabine
6 Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma Active, not recruiting NCT02592538 Not Applicable S-1

Search NIH Clinical Center for Bile Duct Adenocarcinoma

Genetic Tests for Bile Duct Adenocarcinoma

Anatomical Context for Bile Duct Adenocarcinoma

MalaCards organs/tissues related to Bile Duct Adenocarcinoma:

41
Liver, Lung, Breast, Pancreas, Thyroid, Myeloid, Appendix

Publications for Bile Duct Adenocarcinoma

Articles related to Bile Duct Adenocarcinoma:

(show all 18)
# Title Authors Year
1
Intraductal papillary bile duct adenocarcinoma and gastrointestinal stromal tumor in a case of neurofibromatosis type 1. ( 29398874 )
2018
2
An extremely rare case of distal common bile duct adenocarcinoma in a 65-year-old male patient. ( 29940641 )
2018
3
Bile Duct Adenocarcinoma with Acute on Chronic Pancreatitis: A Rare Complication of Long Standing Choledochal Cyst. ( 28764249 )
2017
4
Lung Metastases from Bile Duct Adenocarcinoma Mimicking Chronic Airway Infection and Causing Diagnostic Difficulty. ( 29279503 )
2017
5
Differentiation grade for extrahepatic bile duct adenocarcinoma: Assessed by diffusion-weighted imaging at 3.0-T MR. ( 27776649 )
2016
6
Laryngeal metastasis from bile duct adenocarcinoma. ( 26614301 )
2016
7
Prognostic Value of FDG-PET/CT Total Lesion Glycolysis for Patients with Resectable Distal Bile Duct Adenocarcinoma. ( 26637926 )
2015
8
Common bile duct adenocarcinoma in a patient with situs inversus totalis: report of a rare case. ( 23234596 )
2012
9
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. ( 20224368 )
2010
10
Bile duct adenocarcinoma with minor micropapillary component: a case report. ( 19144165 )
2009
11
Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. ( 18754070 )
2008
12
Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. ( 15191867 )
2004
13
Combined adult-to-adult living donor right lobe liver transplantation and pancreatoduodenectomy for distal bile duct adenocarcinoma in a patient with primary sclerosing cholangitis. ( 14585411 )
2003
14
The role of S100A4 gene encoding an S100-related calcium-binding protein in human bile duct adenocarcinoma cell lines: correlation of S100A4 expression and invasive growth in Matrigel Matrix. ( 11029520 )
2000
15
Bile duct adenocarcinoma mimicking veno-occlusive disease after autologous bone marrow transplantation for acute leukaemia. ( 9674864 )
1998
16
Bile duct adenocarcinoma in a pallid bat (Antrozeous pallidus). ( 6290689 )
1982
17
Bile duct adenocarcinoma with Leser-Trelat sign and pure red blood cell aplasia. ( 6448089 )
1980
18
CLINICOPATHOLOGICAL reports; intrahepatic bile duct adenocarcinoma. ( 14836459 )
1951

Variations for Bile Duct Adenocarcinoma

Expression for Bile Duct Adenocarcinoma

Search GEO for disease gene expression data for Bile Duct Adenocarcinoma.

Pathways for Bile Duct Adenocarcinoma

GO Terms for Bile Duct Adenocarcinoma

Cellular components related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.28 CDH1 CEACAM5 EPCAM IDH1 KRT19 KRT7

Biological processes related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 9.43 HRAS KRAS TP53
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.32 MUC1 TP53
3 response to isolation stress GO:0035900 9.16 HRAS KRAS
4 O-glycan processing GO:0016266 9.13 MUC1 MUC2 MUC5AC
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 HRAS KRAS MUC1 MUC2 MUC5AC

Molecular functions related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 CDH1 CEACAM5 IDH1 PPFIBP2 S100A1 S100A4

Sources for Bile Duct Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....